{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:43Z","timestamp":1790255203834,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201287","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:52:08Z","timestamp":1782852728000},"page":"201287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric AML CAR T cell therapy"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1354-3496","authenticated-orcid":false,"given":"Anand S.","family":"Bhagwat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-7360","authenticated-orcid":false,"given":"Swati","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201287_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106732","article-title":"Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay","volume":"112","author":"Kaleka","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2026.201287_bib2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2010.04.004","volume":"16","author":"Pavletic","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201287_bib3","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fonc.2019.01217","article-title":"The Graft-Versus-Leukemia Effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib4","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201287_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201287_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201287_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201287_bib11","article-title":"Targeting BCMA in multiple myeloma: A comprehensive review of immunotherapeutic strategies and clinical outcomes","volume":"33","author":"Chan","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"O'Hear","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201287_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201287_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omtm.2020.06.024","article-title":"The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing","volume":"18","author":"Riberdy","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201287_bib16","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib17","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib18","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201287_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib20","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201287_bib21","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib22","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib23","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201287_bib24","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201287_bib26","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib27","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1158\/0008-5472.CAN-22-2483","article-title":"LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy","volume":"83","author":"Mai","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201287_bib28","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201287_bib29","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","article-title":"Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201287_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201287_bib31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201287_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41467-022-28243-6","article-title":"CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells","volume":"13","author":"Hebbar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201287_bib34","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201287_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018O ff-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2026.201287_bib36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","article-title":"Will CAR T cell therapy have a role in AML? Promises and pitfalls","volume":"56","author":"Cummins","year":"2019","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.omton.2026.201287_bib39","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201287_bib40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201287_bib41","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib42","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2022-168877","article-title":"Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed\/Refractory AML","volume":"140","author":"Ehninger","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib43","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R\/R) CD123+ Acute Myeloid Leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib44","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib45","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood-2024-208795","article-title":"CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and\/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent\/Refractory Leukemia","volume":"144","author":"Naik","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib46","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2025-1643","article-title":"CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed\/refractory pediatric acute myeloid leukemia","volume":"146","author":"Cain","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib47","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib48","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/bloodadvances.2024014836","article-title":"Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation","volume":"9","author":"Admiraal","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201287_bib49","article-title":"Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR\/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)","volume":"9","author":"Koehne","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib50","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201287_bib51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib53","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","article-title":"Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed\/Refractory Acute Myeloid Leukemia","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201287_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1491341","article-title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201287_bib55","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2024-205229","article-title":"Efficacy and Safety of CAR-T Therapy Targeting CLL1 in Patients with Extramedullary Diseases of Acute Myeloid Leukemia","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib56","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib57","article-title":"First-in-Human CLL1-CD33 Compound CAR (CCAR) T Cell Therapy In Relapsed and Refractory Acute Myeloid Leukemia","author":"Liu","year":"2020","journal-title":"EHA Library."},{"key":"10.1016\/j.omton.2026.201287_bib58","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib59","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1002\/cam4.5916","article-title":"Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia","volume":"12","author":"Pei","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2026.201287_bib60","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","article-title":"CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib61","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201287_bib62","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.3324\/haematol.2017.186742","article-title":"NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed\/refractory acute myeloid leukemia patient","volume":"103","author":"Sallman","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201287_bib63","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201287_bib64","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","article-title":"CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial","volume":"18","author":"Yin","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib65","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/bjh.19446","article-title":"Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression","volume":"204","author":"Jen","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201287_bib66","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3389\/fimmu.2018.02940","article-title":"Overcoming Target Driven Fratricide for T Cell Therapy","volume":"9","author":"Breman","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201287_bib67","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201287_bib68","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.2025032299","article-title":"Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia","volume":"147","author":"Becilli","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201287_bib70","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201287_bib71","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140179","article-title":"Risk-associated alterations in marrow T cells in pediatric leukemia","volume":"5","author":"Bailur","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201287_bib72","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib73","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201287_bib74","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201287_bib75","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201287_bib76","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s43018-025-01054-6","article-title":"Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia","volume":"6","author":"Sanden","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201287_bib77","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.18632\/oncotarget.1504","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia","volume":"5","author":"Folgiero","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201287_bib78","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201287_bib79","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","article-title":"Release of IFNgamma by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells","volume":"28","author":"Corradi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201287_bib80","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/s41375-024-02381-w","article-title":"A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia","volume":"38","author":"Koedijk","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib81","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201287_bib82","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2016-08-734798","article-title":"Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment","volume":"129","author":"Shafat","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib83","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2015-07-655860","article-title":"Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy","volume":"128","author":"Moschoi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib84","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","article-title":"Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets","volume":"186","author":"Michalek","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201287_bib85","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3389\/fonc.2019.01166","article-title":"The Induction of a Permissive Environment to Promote T Cell Immune Evasion in Acute Myeloid Leukemia: The Metabolic Perspective","volume":"9","author":"Mougiakakos","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib86","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjh.19884","article-title":"Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism","volume":"206","author":"Laing","year":"2025","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201287_bib87","first-page":"557","article-title":"Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia","volume":"138","author":"Borella","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib88","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fimmu.2014.00160","article-title":"Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia","volume":"5","author":"Hong","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201287_bib89","doi-asserted-by":"crossref","first-page":"294","DOI":"10.5045\/br.2018.53.4.294","article-title":"Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype","volume":"53","author":"Arandi","year":"2018","journal-title":"Blood Res."},{"key":"10.1016\/j.omton.2026.201287_bib90","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","article-title":"Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation","volume":"103","author":"Meisel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1376554","article-title":"Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations","volume":"12","author":"Guijarro-Albaladejo","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2026.201287_bib92","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2024-194359","article-title":"Potent and Effective Targeting of AML with \u2018Off-the-Shelf\u2019 Engineered CD45-Targeting CAR T-Cells","volume":"144","author":"Shaw","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib93","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201287_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201287_bib95","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201287_bib96","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib97","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2024-206467","article-title":"Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias","volume":"144","author":"Niswander","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib98","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201287_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114260","article-title":"Immunotherapeutic targeting of surfaceome heterogeneity in AML","volume":"43","author":"Bordeleau","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201287_bib100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group","volume":"40","author":"Lamble","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib101","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/bloodadvances.2022008303","article-title":"Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia","volume":"7","author":"Le","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201287_bib102","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.3324\/haematol.2023.283757","article-title":"CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group","volume":"109","author":"Menssen","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201287_bib103","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41375-025-02720-5","article-title":"\u201cBase edited universal\u201d donor CAR T-cell strategies for acute myeloid leukaemia","volume":"39","author":"Kadirkamanathan","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib104","article-title":"Bicistronic CAR T-cells Against CD70 & Active Integrin beta2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia","author":"Kang","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.omton.2026.201287_bib105","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib106","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1038\/s41375-025-02756-7","article-title":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling","volume":"39","author":"Mazzeo","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib107","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","article-title":"Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib108","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201287_bib109","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41571-025-01068-0","article-title":"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia","volume":"22","author":"Glaviano","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib110","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/blood.2025029391","article-title":"FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML","volume":"146","author":"Raj","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib111","doi-asserted-by":"crossref","first-page":"e887","DOI":"10.1016\/S2352-3026(25)00254-6","article-title":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial","volume":"12","author":"Richard-Carpentier","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201287_bib112","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.16229","article-title":"TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia","volume":"188","author":"Cucchi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201287_bib113","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/gcc.23147","article-title":"TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia","volume":"62","author":"Hara","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.omton.2026.201287_bib114","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s44321-024-00024-2","article-title":"Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells","volume":"16","author":"Mueller","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omton.2026.201287_bib115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201287_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1664403","article-title":"Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201287_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032403","article-title":"The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better","volume":"13","author":"Mao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201287_bib118","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.tibtech.2021.12.009","article-title":"Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity","volume":"40","author":"Vander Mause","year":"2022","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omton.2026.201287_bib119","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40164-025-00726-4","article-title":"Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting","volume":"14","author":"Oca\u00f1a-Cara","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201287_bib120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201287_bib121","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/2643-3230.BCD-23-0258","article-title":"CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells","volume":"6","author":"Jambon","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.omton.2026.201287_bib122","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201287_bib123","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201287_bib124","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201287_bib125","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","article-title":"Targeting of intracellular oncoproteins with peptide-centric CARs","volume":"623","author":"Yarmarkovich","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201287_bib126","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omton.2026.201287_bib127","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41587-025-02648-2","article-title":"Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein","volume":"44","author":"George","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201287_bib128","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201287_bib129","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1182\/blood-2025-4176","article-title":"Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+\/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia","volume":"146","author":"Tarlock","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201287_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2025.102524","article-title":"Novel approaches to CAR T cell target identification in acute myeloid leukemia","volume":"82","author":"Hoffmann","year":"2025","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.omton.2026.201287_bib131","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40364-022-00390-4","article-title":"Integrated multiomic approach for identification of novel immunotherapeutic targets in AML","volume":"10","author":"K\u00f6hnke","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omton.2026.201287_bib132","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","article-title":"Structural surfaceomics reveals an AML-specific conformation of integrin beta(2) as a CAR T cellular therapy target","volume":"4","author":"Mandal","year":"2023","journal-title":"Nat. Cancer"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:41:41Z","timestamp":1790253701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001633"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201287","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric AML CAR T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201287"}}